EvlaBio’s website
2 known investors
Find your way into EvlaBio’s website
EVL Bio is developing a selective anti-FGFR4 monoclonal antibody therapy to treat left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD). The therapy blocks pathological FGF23–FGFR4 signaling in cardiomyocytes to prevent maladaptive cardiac hypertrophy and fibrosis.
Founders & leadership
Investors · 2
Frequently asked questions
- What does EvlaBio’s website do?
- EVL Bio is developing a selective anti-FGFR4 monoclonal antibody therapy to treat left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD). The therapy blocks pathological FGF23–FGFR4 signaling in cardiomyocytes to prevent maladaptive cardiac hypertrophy and fibrosis.
- Who founded EvlaBio’s website?
- EvlaBio’s website was founded by Robert Kirmeier, Wenzel von der Heydte.
- Who are EvlaBio’s website's investors?
- EvlaBio’s website's investors include AdBio partners, Kurma Partners.